First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation

Q3 Medicine

Russian Journal of Cardiology Pub Date : 2024-01-10 DOI:10.15829/1560-4071-2024-5747

M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov

引用次数: 0

Abstract

Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.

查看原文本刊更多论文

俄罗斯首次使用 siRNA 药物治疗心脏移植术后患者血脂异常的经验

心脏移植（HT）后的患者罹患心血管疾病的风险非常高。无论性别、年龄和心力衰竭的起因如何，心脏受者的管理方案都包括启动降脂治疗（LLT）。考虑到药物相互作用和移植后并发症的风险，在移植人群中进行降脂治疗的可能性有限。本文介绍了俄罗斯首次使用 siRNA LLT 治疗实体器官移植受者血脂异常的经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Russian Journal of Cardiology Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.20

自引率

0.00%

发文量

185

审稿时长

1 months

期刊介绍： Russian Journal of Cardiology has been issued since 1996. The language of this publication is Russian, with tables of contents and abstracts of all articles presented in English as well. Editor-in-Chief: Prof. Eugene V.Shlyakhto, President of the Russian Society of Cardiology. The aim of the journal is both scientific and practical, also with referring to organizing matters of the Society. The best of all cardiologic research in Russia is submitted to the Journal. Moreover, it contains useful tips and clinical examples for practicing cardiologists. Journal is peer-reviewed, with multi-stage editing. The editorial board is presented by the leading cardiologists from different cities of Russia.